Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource Hepatology, vol.59, pp.318-327, 2014. ,
Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. The Journal of Infectious Diseases, 2018. ,
Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication, World Journal of Gastroenterology, vol.20, issue.11, p.2927, 2014. ,
An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes, Virology, vol.476, pp.355-363, 2015. ,
Natural history of chronic hepatitis C: genotype 1 versus genotype 6, Journal of Hepatology, vol.53, issue.3, pp.444-448, 2010. ,
HCV genotype 6 increased the risk for hepatocellular carcinoma among Asian patients with liver cirrhosis, The American Journal of Gastroenterology, vol.112, issue.7, pp.1111-1119, 2017. ,
, EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol, vol.60, issue.2, 2014.
In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5a inhibitor ledipasvir, Antimicrobial Agents and Chemotherapy, vol.60, issue.3, pp.1847-1853, 2016. ,
HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models, Gastroenterology, vol.154, issue.8, pp.2194-2208, 2018. ,
Impact of preexisting hepatitis c virus genotype 6 NS3, NS5A, and NS5B polymorphisms on the in vitro potency of direct-acting antiviral agents, Antimicrob Agents Chemother, vol.63, issue.4, 2019. ,
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir, PLoS ONE, vol.13, issue.10, p.205186, 2018. ,
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update, Drug Resistance Updates, vol.37, pp.17-39, 2018. ,
An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains. Jhaveri R, ed. PLOS ONE, vol.12, p.179562, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02155275
MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets, Molecular Biology and Evolution, vol.33, issue.7, pp.1870-1874, 2016. ,
Historical epidemiology of hepatitis C virus (HCV) in selected countries, J Viral Hepat, vol.21, pp.5-33, 2014. ,
Performance comparison of the Versant HCV genotype 2.0 assay (LiPA) and the Abbott Realtime HCV genotype II assay for detecting hepatitis C virus genotype 6, J Clin Microbiol, vol.52, issue.10, pp.3685-3692, 2014. ,
Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0, J Clin Microbiol, vol.51, issue.9, pp.2815-2821, 2013. ,
Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures, PLOS ONE, vol.13, issue.3, p.194396, 2018. ,
Using NS5B sequencing for hepatitis C virus genotyping reveals discordances with commercial platforms, PLoS ONE, vol.11, issue.4, p.153754, 2016. ,
Identification of a new HCV subtype 6xg among injection drug users in Kachin, Myanmar. Frontiers in Microbiology, vol.10, 2019. ,
HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens, J Viral Hepat, vol.25, issue.8, pp.969-975, 2018. ,
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies, J Hepatol, vol.68, issue.5, pp.895-903, 2018. ,
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape, J Hepatol, vol.70, issue.3, pp.388-397, 2019. ,
Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance, Antimicrobial Agents and Chemotherapy, vol.59, issue.12, pp.7426-7436, 2015. ,
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection, Hepatol Commun, vol.2, issue.5, pp.595-606, 2018. ,
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity, Antimicrobial Agents and Chemotherapy, vol.58, issue.9, pp.5155-5163, 2014. ,
In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5a inhibitor pibrentasvir, Antimicrobial Agents and Chemotherapy, vol.61, issue.5, pp.2558-2574, 2017. ,
GS-5816, a second generation HCV NS5a inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier, Journal of Hepatology, vol.58, issue.13, pp.61192-61199, 2013. ,
In vitro selection of resistance to sofosbuvir in HCV replicons of genotype 1 to 6, Antiviral Therapy, vol.22, issue.7, pp.587-597, 2017. ,
Naturally occurring resistance-associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 6a-infected patients, BioMed Research International, vol.2017, pp.1-8, 2017. ,
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection, Gastroenterology, vol.149, issue.6, pp.1454-1461, 2015. ,